## AMENDMENTS TO THE CLAIMS

Please amend the claims as follows:

**LISTING OF CLAIMS:**

1-24. (Canceled).

25. (Currently amended): A composition comprising epigallocatechin gallate (EGCG), pantethine, and phytanic acid, which composition is formulated to treat type 2 diabetes.

26. (Currently amended): A nutraceutical composition for treating type 2 diabetes comprising a carrier, epigallocatechin gallate (EGCG), pantethine, and phytanic acid.

27. (Currently amended): A composition comprising epigallocatechin gallate (EGCG), pantethine, and phytanic acid, which composition is formulated to reduce the incidence or risk of type 2 diabetes in a human at risk of developing type 2 diabetes.

28. (Currently amended): A nutraceutical composition for reducing the incidence or risk of type 2 diabetes in a human, the composition comprising a carrier, epigallocatechin gallate (EGCG), pantethine, and phytanic acid.

29. (Cancelled).

30. (Previously presented): The composition according to any one of claims 27 or 28, wherein the human suffers from a condition selected from the group consisting of pre-diabetes, impaired glucose tolerance (IGT), obesity, and combinations thereof.

31. (Previously presented): The composition according to any one of claims 25, 26, 27, or 28, wherein the composition is a food, a beverage, a supplement for a food, or a supplement for a beverage.

32. (Previously presented): The composition according to any one of claims 25, 26, 27, or 28, wherein EGCG is present in an amount sufficient to administer to a subject a daily dosage of 0.3 mg per kg body weight to about 30 mg per kg body weight.

33. (Previously presented): The composition according to any one of claims 25, 26, 27, or 28, wherein phytanic acid is present in an amount sufficient to administer to a subject a daily dosage of 1 mg per kg body weight to about 100 mg per kg body weight.

34. (Currently amended): The composition according to any one of claims 25, 26, 27, or 28 ~~claim 29~~, wherein pantethine is present in an amount sufficient to administer to a subject a daily dosage of 1 mg per kg body weight to about 50 mg per kg body weight.

35. (Currently amended): A unit dosage form for treating type 2 diabetes comprising a carrier, epigallocatechin gallate (EGCG), pantethine, and phytanic acid.

36. (Currently amended): A unit dosage form for reducing the incidence or risk of diabetes type 2 in a human at risk of developing diabetes type 2 comprising a carrier, epigallocatechin gallate (EGCG), pantethine, and phytanic acid.

37. (Cancelled).

38. (Previously presented): The unit dosage form according to claim 36, wherein the human suffers from a condition selected from the group consisting of pre-diabetes, impaired glucose tolerance (IGT), obesity, and combinations thereof.

39. (Previously presented): The unit dosage form according to claim 35 or 36 wherein the unit dosage form contains about 10 mg to about 500 mg of EGCG.

40. (Previously presented): The unit dosage form according to claim 35 or 36 wherein the unit dosage form contains about 30 mg to about 500 mg of phytanic acid.

41. (Currently amended): The ~~composition~~ unit dosage form according to claim 35 or 36 ~~37 wherein the unit dosage form~~ which contains about 20 mg to about 1000 mg of pantethine.

42. (Currently amended): A composition for treating type 2 diabetes comprising epigallocatechin gallate (EGCG), ~~and at least one additional active selected from the group consisting of~~ pantethine, and phytanic acid~~, and combinations thereof~~ in admixture with a food or beverage.

43. (Currently amended): A composition for reducing the incidence or risk of type 2 diabetes in a human, the composition comprising epigallocatechin gallate (EGCG), ~~and at least one additional active selected from the group consisting of~~ pantethine, and phytanic acid~~, and combinations thereof~~ in admixture with a food or beverage.

44. (Previously presented): The composition according to claim 43, wherein the human suffers from a condition selected from the group consisting of pre-diabetes, impaired glucose tolerance (IGT), obesity, and combinations thereof.

45. (Previously presented): The composition according to any one of claims 42 or 43 comprising EGCG, pantethine or a metabolite thereof, phytanic acid, lipoic acid, policosanol and coenzyme Q-10.

46. (Currently amended): A method for treating diabetes in a human comprising administering to the human in need of such treatment a composition comprising epigallocatechin gallate (EGCG), ~~and at least one additional active selected from the group consisting of~~ pantethine, and phytanic acid~~, and combinations thereof~~.

47. (Currently amended): A method for reducing the incidence or risk of diabetes type 2 in a human at risk of developing diabetes type 2 comprising administering to the human a composition comprising epigallocatechin gallate (EGCG), ~~and at least one additional active selected from the group consisting of~~ pantethine, and phytanic acid~~, and combinations thereof~~.

48. (Previously presented): The method according to claim 46, wherein the diabetes is type 1 diabetes.

49. (Previously presented): The method according to claim 47, wherein the diabetes is type 2 diabetes.

50. (Cancelled).

51. (Cancelled).

52. (Cancelled).

53. (Previously presented): The method according to claim 47, wherein the human suffers from a condition selected from the group consisting of pre-diabetes, impaired glucose tolerance (IGT), obesity, and combinations thereof.

54. (Currently amended): The method according to claim 46 or 47, wherein the composition contains EGCG in an amount sufficient to provide a daily dosage of 0.3 mg per kg body weight to about 30 mg per kg body weight of the subject to which it is to be administered, pantethine~~, if present,~~ in an amount sufficient to provide a daily dosage of 1.0 mg per kg body weight to about 50 mg per kg body weight of the subject to which it is to be administered, and phytanic acid~~, if present,~~ in an amount sufficient to provide a daily dosage of 1.0 mg per kg body weight to about 100 mg per kg body weight of the subject to which it is to be administered.